AlloVir (ALVR) plans to raise $252 million in an IPO on Thursday, July 30th, IPO Scoop reports. The company will issue 14,800,000 shares at a price of $16.00-$18.00 per share.
AlloVir has a market-cap of $1 billion.
Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
AlloVir provided the following description of their company for its IPO: ” We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, we have generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced of which has successfully completed a proof-of-concept trial across five viruses and is entering initial pivotal trials for the treatment of virus-associated hemorrhagic cystitis in the fourth quarter of 2020. “.
AlloVir was founded in 2014 and has 21 employees. The company is located at 139 Main Street, Suite 500, Cambridge, MA 02142, US and can be reached via phone at 617-433-2605 or on the web at https://www.AlloVir.com.
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.